Mesa Talks Biggest Breakthroughs in Myelofibrosis in 2021

At ASH 2021, CancerNetwork® spoke with Ruben Mesa, MD, of UT Health San Antonio MD Anderson Cancer Center, about big breakthroughs in the treatment of myelofibrosis over the preceding year.


In myelofibrosis this year, the breakthrough was the growth of the myelofibrosis (MF) pipeline. We’ve had more phase 3 clinical trials in MF this year than we’ve ever had in our history, both in terms of large-scale, single-agent JAK2 inhibitor trials, follow-up series for fedratinib (Inrebic), pacritinib, and momelotinib, and now phase 3 trials in the frontline setting [such as] pelabresib and ruxolitinib (Jakafi), navitoclax and ruxolitinib, and multiple second-line phase 3 studies. This is an explosion of research unlike anything we’ve ever had before, and it makes me deeply excited about the options we’re going to have.

Related Videos
Momelotinib continues to show benefit in reducing splenic symptoms and anemia in myelofibrosis in the second-line setting, making it a likely first treatment choice, according to an expert from the University of Texas MD Anderson Cancer Center .
Ruben Mesa, MD, spoke about the approval of pacritinib and its importance for the treatment of myelofibrosis.
Related Content